**Supplementary Table – Associations between variations in blood pressure and test scores in one year and pharmacological therapy with each class of blood pressure lowering medication according to *APOE* haplotypes**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Assessed Variables | Anti-hypertensive therapy for APOE4+ carriers (*n*=103) | | | | | | | Anti-hypertensive therapy for APOE4- carriers (*n*=88) | | | | | | |
| ACEia (*n*=63) | ATb blocker (*n*=9) | βc-blocker (*n*=9) | CCd blocker (*n*=11) | Diuretice (*n*=30) | None (*n*=25) | ρ | ACEia (*n*=58) | ATb blocker (*n*=13) | βc-blocker (*n*=13) | CCd blocker (*n*=10) | Diuretice (*n*=28) | None (*n*=14) | ρ |
| Systolic blood pressure variations (mmHg) | -14.51 ±18.4 | -16.67 ±15.7 | -10.22 ±10.7 | -17.09 ±17.0 | -7.07 ±18.8 | -4.88 ±13.6 | 0.147 | -13.66 ±17.2 | -10.92 ±16.7 | -10.00 ±14.7 | -8.00 ±23.3 | -12.43 ±17.4 | -9.43 ±11.9 | 0.813 |
| Diastolic blood pressure variations (mmHg) | -6.60 ±10.4 | -7.56 ±13.0 | -2.89 ±6.3 | -7.45 ±7.5 | -3.00 ±10.2 | -2.88 ±8.4 | 0.220 | -5.97 ±11.0 | -4.15 ±7.9 | -3.69 ±9.0 | 1.60 ±13.2 | -4.18 ±8.2 | -1.00 ±7.7 | 0.292 |
| Pulse pressure variations (mmHg) | -7.90 ±13.7 | -9.11 ±12.4 | -7.33 ±10.5 | -9.64 ±15.2 | -4.07 ±14.2 | -2.00 ±9.1 | 0.277 | -7.69 ±12.6 | -6.77 ±16.3 | -6.31 ±14.3 | -9.60 ±17.6 | -8.25 ±14.4 | -8.43 ±8.4 | 0.984 |
| CDR-SOBf variations | 1.71 ±2.4 | 1.06 ±1.6 | 2.33 ±2.7 | 1.95 ±3.0 | 2.02 ±2.8 | 1.54 ±2.8 | 0.889 | 1.37 ±2.0 | 3.23 ±2.9 | 2.04 ±2.3 | 1.80 ±2.6 | 1.43 ±2.4 | 1.50 ±2.7 | 0.333 |
| ADLg variations | -0.56 ±1.5 | -1.56 ±2.5 | -0.89 ±1.5 | -1.18 ±2.3 | -0.73 ±1.8 | -0.72 ±1.5 | 0.940 | -0.45 ±1.4 | -0.69 ±1.3 | -0.92 ±1.8 | -0.30 ±1.3 | -0.54 ±1.8 | -0.36 ±1.6 | 0.871 |
| IADLh variations | -1.70 ±2.6 | -0.67 ±2.5 | -1.56 ±3.6 | -1.55 ±3.3 | -2.03 ±2.8 | -1.72 ±3.4 | 0.971 | -1.14 ±2.2 | -2.77 ±4.5 | -1.69 ±2.3 | -2.10 ±2.8 | -1.11 ±2.0 | -0.64 ±3.1 | 0.703 |
| MMSEi variations | -1.67 ±2.9 | -0.44 ±2.4 | -0.89 ±3.6 | -2.45 ±3.2 | -0.93 ±2.5 | -2.00 ±3.9 | 0.343 | -0.59 ±2.3 | -1.54 ±2.1 | -1.46 ±2.4 | 0.20 ±2.1 | -1.46 ±2.2 | -0.93 ±4.6 | 0.179 |
| CDTj variations | -0.65 ±3.1 | 0.33 ±2.6 | 0.22 ±1.7 | -2.64 ±3.3 | -0.40 ±3.3 | -1.16 ±2.6 | 0.271 | 0.62 ±2.7 | -0.54 ±2.8 | 0.85 ±2.9 | 0.80 ±1.6 | 0.11 ±2.4 | -1.07 ±2.2 | 0.233 |
| Zaritk variations | -1.00 ±7.3 | -0.11 ±4.6 | 4.00 ±7.2 | -0.09 ±7.6 | -0.50 ±7.9 | -2.16 ±9.2 | 0.650 | 0.14 ±9.3 | 5.69 ±9.8 | 3.54 ±14.3 | 5.30 ±8.1 | 3.36 ±9.4 | -1.07 ±9.6 | 0.215 |

a ACEi = angiotensin-converting enzyme inhibitor; APOE4+ carriers: 57 patients used Captopril, 4 patients used Enalapril, and 2 patients used Perindopril; APOE4- carriers: 53 patients used Captopril, 4 patients used Enalapril, and 1 patient used Perindopril.

b AT blocker = angiotensin receptor blocker; APOE4+ carriers: 6 patients used Losartan, and 3 patients used Valsartan; APOE4- carriers: 12 patients used Losartan, and 1 patient used Irbesartan.

c β-blocker; APOE4+ carriers: 7 patients used Atenolol, 1 patient used Propranolol, and 1 patient used Nebivolol; APOE4- carriers: 10 patients used Atenolol, 2 patients used Propranolol, and 1 patient used Carvedilol.

d CC blocker = calcium channel blocker; APOE4+ carriers: 9 patients used Amlodipine, and 2 patients used Nifedipine; APOE4- carriers: 8 patients used Amlodipine, 1 patient used Nifedipine, and 1 patient used Verapamil.

e Diuretic; APOE4+ carriers: 23 patients used Hydrochlorothiazide, 5 patients used Chlorthalidone, 1 patient used Furosemide, and 1 patient used Indapamide; APOE4- carriers: 20 patients used Hydrochlorothiazide, 3 patients used Chlorthalidone, 4 patients used Furosemide, and 1 patient used Indapamide.

f CDR-SOB = Clinical Dementia Rating sum-of-boxes.

g ADL = Index of Independence in Activities of Daily Living.

h IADL = Lawton’s Scale for Instrumental Activities of Daily Living.

i MMSE = Mini-Mental State Examination.

j CDT = Clock Drawing Test.

k Zarit = Brazilian Version of the Zarit Caregiver Burden Interview.